Cargando…

Extra-Intestinal Manifestations of Celiac Disease: What Should We Know in 2022?

Celiac disease (CD) is a chronic, small-intestinal, immune-mediated enteropathy due to gluten exposition in genetically predisposed individuals. It occurs in about 1% of the population and often remains an underdiagnosed condition. This could be due to the fact that the adult population often lacks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durazzo, Marilena, Ferro, Arianna, Brascugli, Isabella, Mattivi, Simone, Fagoonee, Sharmila, Pellicano, Rinaldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746138/ https://www.ncbi.nlm.nih.gov/pubmed/35011999 http://dx.doi.org/10.3390/jcm11010258

Ejemplares similares

Autoimmune Hepatitis and Fibrosis
por: Pellicano, Rinaldo, et al.
Publicado: (2023)

Trends in the Comprehension and Management of Gastrointestinal Tract Disorders
por: Durazzo, Marilena, et al.
Publicado: (2022)

Helicobacter pylori and Respiratory Diseases: 2021 Update
por: Durazzo, Marilena, et al.
Publicado: (2021)

Hepatitis delta virus: From infection to new therapeutic strategies
por: Niro, Grazia A, et al.
Publicado: (2021)

Extra-Esophageal Presentation of Gastroesophageal Reflux Disease: 2020 Update
por: Durazzo, Marilena, et al.
Publicado: (2020)

2013 Update on Celiac Disease and Eosinophilic Esophagitis
por: Pellicano, Rinaldo, et al.
Publicado: (2013)

The Evolving Incidence of Hepatitis C Virus Infection in Italy
por: Pellicano, Rinaldo, et al.
Publicado: (2012)

Response to: Reply on “Renewed Helicobacter pylori Management and Therapy in 2015”
por: Fagoonee, Sharmila, et al.
Publicado: (2016)

One or Two Weeks of Treatment with Helicobacter pylori “Standard” Triple Therapy in the Year 2015?
por: Pellicano, Rinaldo, et al.
Publicado: (2015)

Promises of Fibroblast Growth Factor Receptor–Directed Therapy in Tailored Cancer Treatment
por: Fagoonee, Sharmila, et al.
Publicado: (2020)

Does the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?
por: Fagoonee, Sharmila, et al.
Publicado: (2019)

Extra-Intestinal Manifestation of Celiac Disease in Children
por: Jericho, Hilary, et al.
Publicado: (2018)

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

History of Inflammatory Bowel Diseases
por: Actis, Giovanni Clemente, et al.
Publicado: (2019)

Gluten-Induced Extra-Intestinal Manifestations in Potential Celiac Disease—Celiac Trait
por: Popp, Alina, et al.
Publicado: (2019)

Viruses and celiac disease: what do we know ?
por: Cohen, Ramon, et al.
Publicado: (2023)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm
por: Losurdo, Giuseppe, et al.
Publicado: (2018)

Fatigue as an Extra-Intestinal Manifestation of Celiac Disease: A Systematic Review
por: Jelsness-Jørgensen, Lars-Petter, et al.
Publicado: (2018)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Men's Health: What Should We Know?
por: Kim, Sae Woong
Publicado: (2015)

Circadian Rhythms in Bacterial Sepsis Pathology: What We Know and What We Should Know
por: Mul Fedele, Malena Lis, et al.
Publicado: (2021)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Gastrointestinal Microbiota and Type 1 Diabetes Mellitus: The State of Art
por: Durazzo, Marilena, et al.
Publicado: (2019)

Extra-criteria clinical manifestations of antiphospholipid antibody should not be ignored
por: Huang, Can, et al.
Publicado: (2022)

Low Carbohydrate and Low-Fat Diets: What We Don’t Know and Why We Should Know It
por: Seid, Heather, et al.
Publicado: (2019)

Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?
por: Cortese, Rosa, et al.
Publicado: (2022)

Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases
por: Cernigliaro, Viviana, et al.
Publicado: (2020)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Lessons in hand washing: what we should know?
por: Egwari, LO, et al.
Publicado: (2015)

Drug Allergy in Children: What Should We Know?
por: Park, Ji Soo, et al.
Publicado: (2019)

Foliar mineral nutrient uptake in carnivorous plants: what do we know and what should we know?
por: Adamec, Lubomír
Publicado: (2013)

We Know Liver Biochemistries Are Elevated in COVID-19, But Should We Be Concerned?
por: Bloom, Patricia P., et al.
Publicado: (2020)

Neuropathic pain; what we know and what we should do about it
por: Smith, Peter A.
Publicado: (2023)

What we know about ocular manifestations of Ebola
por: Moshirfar, Majid, et al.
Publicado: (2014)

Bronchoalveolar lavage fluid dilution in ICU patients: what we should know and what we should do
por: Yu, Yuetian, et al.
Publicado: (2019)

Commentary: What we should know about our learners
por: Groth, Shawn S., et al.
Publicado: (2020)

Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?
por: Li, Xiaoming, et al.
Publicado: (2022)

Incidental Pulmonary Nodules - What Do We Know in 2022
por: Schmid-Bindert, Gerald, et al.
Publicado: (2022)

Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
por: Shahgolzari, Mehdi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p04uvmvaims84lonkgho0ipahs